Drugs / C134
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06614855 | Jun 2025 → Jan 2027 expected | astrocytoma (excluding glioblastoma), gliosarcoma, grade III glioma | James Markert, MD | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06193174 | Jun 2024 → Mar 2025 | anaplastic astrocytoma, gliosarcoma | University of Alabama at Birmingham | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03657576 | Sep 2019 → Oct 2024 overdue | anaplastic astrocytoma, gliosarcoma | University of Alabama at Birmingham | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-04-13 | Mustang Bio, Inc. | Results Mustang Bio Announces a Phase 1 Clinical Trial Combining MB-101 (IL13Rα2‐targeted CAR T cell therapy) and MB-108 (C134 oncolytic virus) for the Treatment of Glioblastoma mustangbio.com ↗ |
| 2019-05-16 | Mustang Bio, Inc. | Regulatory Mustang Bio and Nationwide Children’s Hospital Receive Orphan Drug Designation for MB-108 (Oncolytic Virus C134) for the Treatment of Malignant Glioma mustangbio.com ↗ |
All press releases naming this drug 4 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C134 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03657576 ↗ |
| Known as | IRS-1 HSV | “A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma” NCT06614855 ↗ |
| Route | Other | “Administered intratumorally” NCT06193174 ↗ |